Harinad Babu Maganti

Dr. Harinad Babu Maganti


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in Cytotherapy
Verified
Journal Article
Closed access
BBBryenah Bennett
Bryenah Bennett
JHJustine Hanotaux
Justine Hanotaux
APAjay Ratan Pasala
Ajay Ratan Pasala
THTanvir Hasan
Tanvir Hasan
DHDhuha Hassan
Dhuha Hassan
HMHarinad Babu Maganti
Harinad Babu Maganti

23 January 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
THTanvir Hasan
Tanvir Hasan
APAjay Pasala
Ajay Pasala
DHDhuha Hassan
Dhuha Hassan
JHJustine Hanotaux
Justine Hanotaux
DADavid Allan
David Allan
HMHarinad Babu Maganti
Harinad Babu Maganti
Hematopoietic stem-cell (HSC) transplantation (HSCT) is used to treat various hematologic disorders. Use of genetically modified mouse models of hematopoietic cell transplantation has been critical in our fundamental understanding of HSC biology and in developing approaches for human patients. Pre-clinical studies in animal models provide insight into the journey of transplanted HSCs from infusion to engraftment in bone-marrow (BM) niches. Various signaling molecules and growth factors secreted by HSCs and the niche microenvironment play critical roles in homing and engraftment of the transplanted cells. The sustained equilibrium of these chemical and biologic factors ensures that engrafted HSCs generate healthy and durable hematopoiesis. Transplanted healthy HSCs compete with residual host cells to repopulate stem-cell niches in the marrow. Stem-cell niches, in particular, can be altered by the effects of previous treatments, aging, and the paracrine effects of leukemic cells, which create inhospitable bone-marrow niches that are unfavorable for healthy hematopoiesis. More work to understand how stem-cell niches can be restored to favor normal hematopoiesis may be key to reducing leukemic relapses following transplant.

26 November 2024
Verified
Book Chapter
Closed access
PDF file
WKWoratree Kaewsakulthong
Woratree Kaewsakulthong
APAjay Ratan Pasala
Ajay Ratan Pasala
JHJustine Hanotaux
Justine Hanotaux
THTanvir Hasan
Tanvir Hasan
HMHarinad Babu Maganti
Harinad Babu Maganti

27 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
THTanvir Hasan
Tanvir Hasan
APAjay Pasala
Ajay Pasala
DHDhuha Hassan
Dhuha Hassan
JHJustine Hanotaux
Justine Hanotaux
DADavid Allan
David Allan
HMHarinad Babu Maganti
Harinad Babu Maganti
Hematopoietic stem cell (HSC) transplantation (HSCT) is used to treat various hematologic disorders. Use of genetically modified mouse models of hematopoietic cell transplantation have been critical in our fundamental understanding of HSC biology and developing approaches for human patients. Pre-clinical studies in animal models provide insight into the journey of transplanted HSCs from infusion to engraftment in bone marrow (BM) niches. Various signaling molecules and growth factors secreted by HSCs and the niche microenvironment play critical roles in homing and engraftment of the transplanted cells. The sustained equilibrium of these chemical and biologic factors ensures that engrafted HSCs generate healthy and durable hematopoiesis. Transplanted healthy HSCs compete with residual host cells to repopulate stem cell niches in the marrow. Stem cell niches, in particular, can be altered by the effects of previous treatments, aging, and paracrine effects of leukemic cells that create inhospitable bone marrow niches that are unfavorable for healthy hematopoiesis. More work to understand how stem cell niches can be restored to favour normal hematopoieis may be key to reducing leukemic relapses following transplant.